Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
Completed
Sanofi
Phase 2
2011-01-01
The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in
participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
Completed
Regeneron Pharmaceuticals
Phase 2
2011-01-01
The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in
participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Completed
Regeneron Pharmaceuticals
Phase 2
2011-01-01
Primary Objective:
- To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein
cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in
participants with LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) on ongoing stable atorvastatin
therapy.
Secondary Objectives:
- To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment
in comparison with placebo
- To evaluate the safety and tolerability of alirocumab
- To evaluate the development of anti-alirocumab antibodies
- To evaluate the pharmacokinetics of alirocumab
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Completed
Sanofi
Phase 2
2011-01-01
Primary Objective:
- To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein
cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in
participants with LDL-C ≥ 100 mg/dL (≥ 2.59 mmol/L) on ongoing stable atorvastatin
therapy.
Secondary Objectives:
- To evaluate the effects of alirocumab on other lipid levels after 12 weeks of treatment
in comparison with placebo
- To evaluate the safety and tolerability of alirocumab
- To evaluate the development of anti-alirocumab antibodies
- To evaluate the pharmacokinetics of alirocumab
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
